Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 428-432

  Metallidis, Simeon ^a   Charokopos, Nikolaos ^a   Nikolaidis, John ^a   Alexiadou, Efi ^b   Lazaraki, Georgia ^a   Koumentaki, Eleni ^a   Tsona, Afroditi ^a   Theodoridis, Georgios ^b   Nikolaidis, Pavlos ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bone; HPLC; Moxifloxacin; Osteomyelitis; Penetration

Indexed keywords

AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CARDIOPULMONARY BYPASS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MANUBRIUM; MIDDLE AGED; OSTEOMYELITIS; QUINOLINES; STERNUM;

EID: 33750334200     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.019     Document Type: Article

References (30)

1. Scholl L., Chang E., Reitz B., and Chang J. Sternal osteomyelitis: use of vacuum-assisted closure device as an adjunct to definitive closure with sternectomy and muscle flap reconstruction. J Card Surg 19 (2004) 453-461
2. Ross J.J., and Shamsuddin H. Sternoclavicular septic arthritis: review of 180 cases. Medicine (Baltimore) 83 (2004) 139-148
3. Gummert J.F., Barten M.J., Hans C., et al. Mediastinitis and cardiac surgery-an updated risk factor analysis in 10,373 consecutive adult patients. Thorac Cardiovasc Surg 50 (2002) 87-91
4. Alos JI. Quinolones. Enferm Infecc Microbiol Clin 2003;21:261-7; quiz 268, 272 [in Spanish].
5. Lew D.P., and Waldvogel F.A. Quinolones and osteomyelitis: state-of-the-art. Drugs 49 Suppl. 2 (1995) 100-111
6. Fitton A. The quinolones. An overview of their pharmacology. Clin Pharmacokinet 22 Suppl. 1 (1992) 1-11
7. Keating G.M., and Scott L.J. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 64 (2004) 2347-2377
8. Iakovlev V.P., and Polushkina N.R. Moxifloxacin: results of clinical use. Antibiot Khimioter 47 (2002) 32-36 [in Russian]
9. MacGowan A.P., Rogers C.A., Holt H.A., and Bowker K.E. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 47 (2003) 1088-1095
10. Ince D., Zhang X., and Hooper D.C. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 1410-1415
11. Schaumann R., Goldstein E.J., Forberg J., and Rodloff A.C. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54 (2005) 749-753
12. Malincarne L., Ghebregzabher M., Moretti M.V., et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 57 (2006) 950-954
13. Mousa H.A. Bone infection. East Mediterr Health J 9 (2003) 208-214
14. Lew D.P., and Waldvogel F.A. Osteomyelitis. Lancet 364 (2004) 369-379
15. Shapiro F. Osteopetrosis. Current clinical considerations. Clin Orthop Relat Res (1993) 34-44
16. Mandracchia V.J., Sanders S.M., Jaeger A.J., and Nickles W.A. Management of osteomyelitis. Clin Podiatr Med Surg 21 (2004) 335-351 vi
17. Karwowska A., Davies H.D., and Jadavji T. Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy. Pediatr Infect Dis J 17 (1998) 1021-1026
18. Gillespie W.J. Epidemiology in bone and joint infection. Infect Dis Clin North Am 4 (1990) 361-376
19. Garazzino S., Aprato A., Maiello A., et al. Osteomyelitis caused by Enterobacter cancerogenus infection following a traumatic injury: case report and review of the literature. J Clin Microbiol 43 (2005) 1459-1461
20. Snyder R.J., Cohen M.M., Sun C., and Livingston J. Osteomyelitis in the diabetic patient: diagnosis and treatment. Part 1: overview, diagnosis, and microbiology. Ostomy Wound Manage 47 (2001) 18-22 25-30; quiz 31-2
21. Snyder R.J., Cohen M.M., Sun C., and Livingston J. Osteomyelitis in the diabetic patient: diagnosis and treatment. Part 2: medical, surgical, and alternative treatments. Ostomy Wound Manage 47 (2001) 24-30 32-41; quiz 42-3
22. Farley M.M. Group B streptococcal infection in older patients. Spectrum of disease and management strategies. Drugs Aging 6 (1995) 293-300
23. Garcia-Lechuz J.M., Bachiller P., Vasallo F.J., Munoz P., Padilla B., and Bouza E. Group B streptococcal osteomyelitis in adults. Medicine (Baltimore) 78 (1999) 191-199
24. Pascual A., and Garcia I. Penetration and intracellular activity of fluoroquinolones. Enferm Infecc Microbiol Clin 16 (1998) 138-143 [in Spanish]
25. Wispelwey B., and Scheld W.M. Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis. A review. Diagn Microbiol Infect Dis 13 (1990) 169-171
26. Talley J.H. Fluoroquinolones. New miracle drugs?. Postgrad Med 89 (1991) 101-103 106-8, 111-3
27. Mandal S., Berendt A.R., and Peacock S.J. Staphylococcus aureus bone and joint infection. J Infect 44 (2002) 143-151
28. Betriu C., Gomez M., Palau M.L., Sanchez A., and Picazo J.J. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother 43 (1999) 2320-2322
29. Perez-Trallero E., Garcia-Rey C., Martin-Sanchez A.M., Aguilar L., Garcia-de-Lomas J., and Ruiz J. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 46 (2002) 2665-2667
30. Biedenbach D.J., Jones R.N., and Pfaller M.A. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagn Microbiol Infect Dis 39 (2001) 245-250